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Abstract
Patients with pancreatic adenocarcinoma are known to have a high mortality rate. The 5-year 
survival rate still remains low even now compared to that of the 1960’s despite new advances in 
management including surgery, chemotherapy, pathological classifi cation and molecular diagnostic 
technologies.  Precursors to invasive pancreatic adenocarcinoma have been identifi ed in the last ten 
years that include mucinous cystic neoplasm, intraductal papillary mucinous neoplasm and pancreatic 
intraepithelial neoplasia.  p53 protein accumulation in the nuclei is a common molecular event in 
most human neoplasms.  Our objective is to investigate p53 expression in pancreatic adenocarcinoma 
and precursor lesions and their signifi cance.  The selected study material encompassed 31 invasive 
ductal adenocarcinoma, 15 mucinous cystic neoplasm and papillary mucinous neoplasm, and 27 
cases of pancreatic intraepithelial neoplasia including grade 1, 2 and 3.  Immunoscore was given 
for each case based on intensity of staining and percentage of cells positive and compared between 
precursor lesions and invasive adenocarcinoma. A score of 50 and above was considered signifi cant. 
The results showed that p53 expression increased progressively and signifi cantly with the grade of 
pancreatic intraepithelial neoplasia and adenocarcinoma (p-value < 0.001).  These fi ndings support the 
concept of multistep carcinogenesis in pancreatic adenocarcinoma and suggest that p53 inactivation 
occurs in the progression of precursors to pancreatic adenocarcinoma.
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ORIGINAL ARTICLE
INTRODUCTION
Adenocarcinoma of the pancreatic duct constitutes 
85% of all pancreatic malignancy.1 In the United 
States, it is the fourth most common cause of death 
from cancer.2 In Japan, it is the fi fth most common 
cause of cancer death and the fi ve-year survival 
rate is 5.5%. This is mainly due to late stage at 
presentation as more than 40% of patients with 
pancreatic cancers are detected at stage IV B.3 
The Malaysian National Cancer registry data of 
2003 showed that pancreatic adenocarcinoma is 
rare in Malaysia and constituted only 1.2% of all 
reported cancers.4  Non-invasive precursor lesions 
of the pancreatic ducts have been observed in 
resected pancreata and autopsy tissues.5,6,7  It was 
suggested that the detection and prevention of 
these lesions may offer a cure in early pancreatic 
cancers.  The recent classifi cation of non-invasive 
epithelial lesions by Hruban et al8 includes 
pancreatic intraepithelial neoplasia (PanIN), 
intraductal papillary mucinous neoplasm (IPMN) 
and mucinous cystic neoplasm (MCN).  PanIN 
has been further subdivided into 1A, 1B, 2 and 
3 based on morphology and grade of dysplasia. 
Likewise, IPMN and MCN have been classifi ed 
into adenoma, borderline and carcinoma in-situ 
based on the grade of dysplasia.8,9   It is well 
known that TP53 gene is one of the most common 
targets for mutation in many cancers. Hermanova 
et al10 noted that proportion of p53 protein 
expression increased progressively from normal 
pancreatic duct, to precursor lesions to invasive 
adenocarcinoma. The purpose of this study is 
to investigate the p53 immunohistochemical 
expression profi le in pancreatic adenocarcinoma 
and precursor lesions. 
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MATERIALS AND METHODS
This is a retrospective study.  A total of 180 cases 
of pancreatic resection specimens were received 
by the Department of Pathology of Selayang 
Hospital between 2005 to 2010. Histological 
sections from these cases were reviewed.  The 
selected study material included 31 invasive 
pancreatic ductal adenocarcinoma and 15 non-
invasive IPMN/MCN.  Furthermore, 27 PanIN 
lesions detected in 15 cases of invasive ductal 
carcinoma, 8 cases of chronic pancreatitis and 
4 cases from benign cystic neoplasms were 
included in the study (Table 1). In the cases 
of invasive pancreatic cancer, PanIN lesions 
were selected from outside the invasive cancer 
nests. PanIN lesions were classifi ed according 
to Hruban et al into PanIN-1A, PanIN-1B, 
PanIN-2 and PanIN-3 lesions.8 The PanIN-1A 
lesions show columnar cells with abundant apical 
cytoplasmic mucin, basally located nuclei while 
PanIN-1B lesions in addition have well formed 
papillae.  Since both PanIN-1A and B have no 
nuclear atypia, they were grouped together as 
PanIN-1 in this study.  In view of the small 
numbers of IPMN and MCN cases, they were 
grouped together, but separated according to the 
grade of dysplasia such as benign (adenoma), 
moderate (borderline) and carcinoma-in-situ.   
p53 immunohistochemistry
Histological sections cut at 4μm were made 
from representative formalin-fi xed, paraffi n-
embedded blocks of the selected lesions.  The 
slides were mounted on polylysine coated glass 
slides and examined for p53 immunoreactivity 
against a monoclonal mouse anti-human p53 
protein clone DO-7 (1:25 dilution) obtained 
commercially from DAKO using the standard 
avidin-biotin complex immunoperoxidase (IP) 
method with overnight incubation.  Sections from 
ovarian serous adenocarcinoma that revealed 
strong positivity for p53 were used as positive 
controls. Negative controls were performed 
by incubating the sample without the primary 
antibodies.  For each selected PanIN, IPMN, 
MCN and adenocarcinoma, the entire lesion 
in the section was analyzed under high power 
(magnifi cation X400) microscopy and evaluated 
for p53 expression (Figure 1) and only nuclear 
staining is considered positive.  
 The p53 immunoscore was obtained by 
multiplying the percentage of positive cells 
with the numeric score based on the previous 
published criteria by Hermanova et al.10  The 
numeric score was given as follows: score 0 - 
no staining,  nuclei stained blue; score 1- weak 
staining, nuclei blue-brown; score 2 - nuclei 
brown; and score 3- nuclei deep brown or black. 
Scores of above 50 were considered signifi cantly 
raised. 
 Statistical analysis was done using SPSS 
version 17.0.  As mentioned before, the IPMN 
and MCN were grouped together as the numbers 
were very small.  PanIN-1A and PanIN-1B were 
categorized as one group i.e. PanIN-1.  Statistical 
TABLE 1: Histopathological background of pancreatic intraepithelial neoplasms (PanIN) 
included in the study
Pathological diagnosis Number of  Pancreatic intraepithelial neoplasm 
 PanIN-1 PanIN-2 PanIN-3
Adenocarcinoma 7 4 4
Chronic pancreatitis 2 5 1
Serous cystadenoma 1 0 0
Mucinous cystic neoplasm 1 0 0
Intraductal papillary  2 0 0
mucinous neoplasm 
Total 13 9 5
PanIN-1= Pancreatic intraepithelial neoplasia 1;  PanIN-2 = Pancreatic intraepithelial neoplasia 2; 
PanIN-3= Pancreatic intraepithelial neoplasia 3.
91
P53 IN PANCREATIC CARCINOMA
analysis was performed using the cross tabulation 
and chi square test.  A p value of <0.05 was 
considered statistically signifi cant.
RESULTS
There were 13 cases of PanIN-1 (Figure 2), 9 
cases of PanIN-2 (Figure 3), 5 cases of PanIN-3 
(Figure 4), 11 cases of MCN (Figure 5) and 4 
cases of IPMN. Two cases each of IPMN and 
MCN were categorized under borderline tumour 
in view of epithelial dysplasia.  There were 31 
cases of pancreatic adenocarcinoma.  There was 
no case of carcinoma in situ in the study.
 Results of p53 expression in pancreatic 
adenocarcinoma and precursor lesions are given 
in Table 2.   
 A majority of those with adenoma of IPMN/
MCN, PanIN-1, PanIN-2 have immunoscores 
of less than 10, whereas, a majority of those 
with PanIN-3 and adenocarcinoma have 
immunoscores of 150-300.  However, the 
minimum expected count is only 0.44, which 
is very low, due to the small sample size of 73. 
The chi-square value is 63.121 and the p-value 
is less than 0.001.  Thus, there is a signifi cant 
association between p53 expression and various 
precursor lesions.
FIG. 1: p53 immunopositivity in pancreatic intraepithelial neoplasia 3 (arrow) and negative in normal gland 
(narrow arrow). Magnifi cation x 40.
FIG. 2:  Pancreatic intraepithelial neoplasia 1. Glands lined by mucinous columnar epithelial cells with basally 
located nuclei. H&E stain x 100.
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FIG. 4:  Pancreatic intraepithelial neoplasia 3. Glands showing budding of cellular tufts with nuclear atypia. H&E 
stain x 100.
FIG. 3:  Pancreatic intraepithelial neoplasia 2. Glands exhibiting nuclear stratifi cation. H&E stain x 100.
FIG. 5:  Benign mucinous cystic neoplasm.  H&E stain x 40.
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DISCUSSION
In this study, it was found that there is a 
progressive increment in p53 expression from 
adenoma, to borderline IPMN/MCN, PanIN- 
1, 2 and 3, and adenocarcinoma.  Among the 
adenoma of IPMN/MCN, all 11 cases showed p53 
expression below the immunoscore of 50. Among 
the PanIN-1 lesions, 77% of p53 expression had 
immunoscores of <10 and 23% scored between 
11 and 49. Among the PanIN- 2 lesions, 56% of 
p53 expression had immunoscores of < 10. In 
addition, a good proportion (33.3%) of the scores 
was between 50 and 149, while 11% were in the 
150-300 range, indicating a progression of p53 
expression.  Among the PanIN- 3 lesions, the 
lower level immunoscore scores were equal in 
proportion, while the 150-300 level was twice as 
much. The progressive p53 expression is most 
evident in the adenocarcinoma lesion.  Overall, 
there is a progressive p53 expression in the 
different lesions, though it is less conclusive 
due to the small numbers of samples in some 
of the categories.  In this study, an alternative 
would have been the grouping of the Pan IN 
lesions into one, but this would cause loss of 
information of the expression of p53 on these 
precursor lesions. The other alternative would 
have been the grouping of the immunoscores into 
smaller number of levels. However, this would 
not show progressive p53 expression across all 
the immunoscore ranges. Thus, the best option 
is to increase the sample size. A bigger sample 
size would have given a clearer picture of p53 
progression. Therefore, it is highly recommended 
that for future studies, the sample size should 
be increasd. This can be done by conducting 
multicentre studies.  
 The progressive trend of p53 expression in 
PanIN-1, PanIN-2, PanIN-3 and adenocarcinoma 
is also in line with other studies.10,11,12.  Abe et 
al12 compared p53 expression between IPMN 
and PanIN adjusted according to the same 
histological grade.  PanIN-1 is thought to be 
equivalent to IPMN with no dysplasia, PanIN-2 
to borderline IPMN that is characterized by 
moderate dysplasia and PanIN-3 corresponded 
to IPMN with severe dysplasia/carcinoma in situ. 
They did not include MCN. Their study showed 
that there were no signifi cant differences between 
lower grade IPMN and lower grade PanIN 
lesions whereas p53 expression was signifi cantly 
higher among PanIN-3 than IPMN with severe 
dysplasia.  In our study, little difference in p53 
immunoscore was observed between PanIN-1 
and adenoma of IPMN/MCN.  On the other 
hand, we have only 4 borderline tumours and no 
carcinoma-in-situ.  All the 4 borderline tumours 
showed (Table 2) scores of 50-149.  Fisher exact 
test was conducted to compare the immunoscore 
between borderline IPMN/MCN and PanIN-2. 
After collapsing 50-149 and 150-300 expression 
levels, the p-value from Fisher’s Exact Test was 
TABLE 2: Expression of p53 in pancreatic intraepithelial neoplasia, intraductal papillary 
mucinous neoplasm, mucinous cystic neoplasm and pancreatic adenocarcinoma 
Lesion p53 expression immunoscore  
 <10 10-49 50-149 150-300 Total
IPMN/MCN  10(90.9%) 1(9.1%) 0 0 11(100%)
(adenoma) 
IPMN/MCN
(borderline) 0 0 4(100%) 0 4(100%)
PanIN-1 10(76.9%) 3(23.1%) 0 0 13(100%)
PanIN -2 5(55.6%) 0 3(33.3%) 1(11.1%) 9(100%)
PanIN-3 1(20%) 1(20%) 1(20%)     2(40%) 5(100%)
Adenocarcinoma 2(6.5%) 3(9.7%) 8(25.8%) 18(58.1%) 31(100%)
Total 28(38.4%) 8(11%) 16(21.%) 21(28.8%) 73(100%)
     
Person Chi-Square = 63.121, df = 15 , p-value < 0.001. Minimum expected count = 0.44
PanIN-1= Pancreatic intraepithelial neoplasia 1. PanIN-2 = Pancreatic intraepithelial neoplasia 2
PanIN-3= Pancreatic intraepithelial neoplasia 3. PMN= Intraductal papillary mucinous neoplasm
MCN = Mucinous cystic neoplasm
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0.098, which is more than 0.05. Thus, there is 
no difference in expression between these 2 
groups.  Comparison between PanIN-3 lesions 
with carcinoma in situ of IPMN/MCN cannot 
be made because of the absence of case. Our 
study is somewhat different from other previous 
studies because this study also includes MCN. 
The purpose of this study is to investigate p53 
expression in pancreatic adenocarcinoma and 
its precursor lesions. We found a signifi cant 
association between p53 expression and the 
various precursor lesions, suggesting that p53 
expressions may be helpful in evaluating the 
progression of the different precursor lesions. 
However, the minimum expected count is only 
0.44. This is due to the small sample size of only 
73. This is one of the limitations of this study.
CONCLUSION
These fi ndings show signifi cant p53 expression 
in pancreatic adenocarcinoma and the precursor 
lesions, which support the concept of multistep 
carcinogenesis in pancreatic adenocarcinoma. It 
also suggests that p53 inactivation occurs in the 
progression of preinvasive to invasive lesions. 
Future studies with large sample sizes should be 
conducted to strengthen these fi ndings and may 
help develop a strategy for early recognition and 
management of pancreatic duct cancer.
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